Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Revance Therapeutics
(NQ:
RVNC
)
2.920
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Revance Therapeutics
< Previous
1
2
3
4
5
6
7
8
9
Next >
ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Revance Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
November 01, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
REVANCE THERAPEUTICS SHAREHOLDER ALERT
October 31, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Exposures
Product Safety
REVANCE THERAPEUTICS INVESTOR ALERT
October 29, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Exposures
Product Safety
REVANCE THERAPEUTICS UPDATE
October 28, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Exposures
Product Safety
INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Revance Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
October 28, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
REVANCE THERAPEUTICS SHAREHOLDER NOTICE
October 27, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Exposures
Product Safety
REVANCE THERAPEUTICS SHAREHOLDER ALERT
October 26, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Exposures
Product Safety
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Revance Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
October 26, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
REVANCE THERAPEUTICS INVESTOR ALERT
October 25, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Exposures
Product Safety
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Revance Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
October 25, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
REVANCE THERAPEUTICS SHAREHOLDER ALERT
October 24, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Exposures
Product Safety
REVANCE THERAPEUTICS INVESTOR ALERT
October 22, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Exposures
Product Safety
REVANCE THERAPEUTICS UPDATE
October 21, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Exposures
Product Safety
ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Revance Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
October 21, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
REVANCE THERAPEUTICS SHAREHOLDER NOTICE
October 20, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Exposures
Product Safety
ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Revance Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
October 20, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
REVANCE THERAPEUTICS SHAREHOLDER ALERT
October 19, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Exposures
Product Safety
Lost Money in Revance Therapeutics, Inc.?
October 18, 2021
From
Gibbs Law Group
Via
Business Wire
REVANCE THERAPEUTICS INVESTOR ALERT
October 18, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Exposures
Product Safety
REVANCE ALERT: Bragar Eagel & Squire, P.C. is Investigating Revance Therapeutics, Inc. on Behalf of Revance Stockholders and Encourages Investors to Contact the Firm
October 15, 2021
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
Revance Provides Regulatory Update on DaxibotulinumtoxinA for Injection for the Treatment of Moderate to Severe Glabellar (Frown) Lines
October 15, 2021
From
Revance Therapeutics, Inc.
Via
Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Revance Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
October 15, 2021
From
The Schall Law Firm
Via
Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Revance Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
October 14, 2021
From
The Schall Law Firm
Via
Business Wire
RVNC BREAKING NEWS: ROSEN, A TOP RANKED LAW FIRM, Encourages Revance Therapeutics, Inc. Investors with Losses to Inquire About Class Action Investigation – RVNC
October 14, 2021
From
Rosen Law Firm
Via
Business Wire
Revance Continues to Anticipate FDA Approval of DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines in 2021
October 12, 2021
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Announces the Launch of OPUL™, the First-of-its-Kind Relational Commerce Platform for Aesthetic Practices
October 11, 2021
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Showcase Data from Phase 3 ASPEN-1 Clinical Trial Evaluating Efficacy, Duration of Effect and Safety of DaxibotulinumtoxinA for Injection for Cervical Dystonia at International Parkinson and Movement Disorder Society Virtual Congress 2021
September 16, 2021
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Presents Data on the RHA® Collection of Dermal Fillers at the 2021 Virtual Skin of Color Update Meeting
September 10, 2021
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Participate in the Wells Fargo Securities Healthcare Conference
September 02, 2021
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Announces Publication of Results on Static Glabellar Lines With Repeated Treatment of DaxibotulinumtoxinA for Injection From the SAKURA Clinical Program in Dermatologic Surgery
September 01, 2021
From
Revance Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.